Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paliperidone Palmitate

FDA-approved product (suspension, extended release, intramuscular), marketed as Erzofri, Invega Hafyera, Invega Sustenna and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paliperidone Palmitate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paliperidone Palmitate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paliperidone Palmitate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

    NCT01947803 · start 2013-09

    Registered record
    Registry ID
    NCT01947803
    Conditions
    Schizophrenia
    Interventions
    Paliperidone Palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2015-03
    Enrolment
    353

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone Palmitate
    PhasePhase 4
    Registry statusCompleted

  • A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders

    NCT01742390 · start 2013-02

    Registered record
    Registry ID
    NCT01742390
    Conditions
    Sexual Dysfunction; Hyperprolactinemia
    Interventions
    Aripiprazole; risperidone or paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2014-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexual Dysfunction; Hyperprolactinemia
    InterventionAripiprazole; risperidone or paliperidone
    PhasePhase 4
    Registry statusUnknown

  • A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

    NCT01822730 · start 2013-02

    Registered record
    Registry ID
    NCT01822730
    Conditions
    Methamphetamine Dependence
    Interventions
    paliperidone; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-02
    Completion
    2014-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethamphetamine Dependence
    Interventionpaliperidone; Risperidone
    PhasePhase 4
    Registry statusCompleted

  • A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

    NCT01529515 · start 2012-05

    Registered record
    Registry ID
    NCT01529515
    Conditions
    Schizophrenia
    Interventions
    PP3M 175 mg eq.; PP3M 263 mg eq.; PP3M 350 mg eq.; PP3M 525 mg eq.; Placebo (20% Intralipid emulsion)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-04
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPP3M 175 mg eq.; PP3M 263 mg eq.; PP3M 350 mg eq.; PP3M 525 mg eq. +1 more
    PhasePhase 3
    Registry statusCompleted

  • Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

    NCT01451736 · start 2011-10

    Registered record
    Registry ID
    NCT01451736
    Conditions
    Schizophrenia (Recent-onset)
    Interventions
    paliperidone palmitate; risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2021-12-31
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia (Recent-onset)
    Interventionpaliperidone palmitate; risperidone
    PhasePhase 4
    Registry statusCompleted

  • Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

    NCT01399450 · start 2011-08

    Registered record
    Registry ID
    NCT01399450
    Conditions
    Schizophrenia
    Interventions
    paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-08
    Completion
    2016-11
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

    NCT01193153 · start 2010-09

    Registered record
    Registry ID
    NCT01193153
    Conditions
    Schizoaffective Disorder
    Interventions
    Placebo; paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2013-10
    Enrolment
    667

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizoaffective Disorder
    InterventionPlacebo; paliperidone palmitate
    PhasePhase 3
    Registry statusCompleted

  • Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

    NCT01181960 · start 2010-08

    Registered record
    Registry ID
    NCT01181960
    Conditions
    Schizophrenia; Bipolar Disorder
    Interventions
    Risperidone long acting injectable - New Starts; Risperidone long acting injectable - Continuous Users; Paliperidone Palmitate -New and Continuous Users; Other Antipsychotics - New Starts
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2013-11
    Enrolment
    1,066

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Bipolar Disorder
    InterventionRisperidone long acting injectable - New Starts; Risperidone long acting injectable - Continuous Users; Paliperidone Palmitate -New and Continuous Users; Other Antipsychotics - New Starts
    PhaseNot recorded
    Registry statusCompleted

  • 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

    NCT01157351 · start 2010-05

    Registered record
    Registry ID
    NCT01157351
    Conditions
    Schizophrenia
    Interventions
    paliperidone; risperidone; haloperidole; perphenazine; aripiprazole; quetiapine; paliperidone palmitate; olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-05
    Completion
    2013-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone; risperidone; haloperidole; perphenazine +4 more
    PhasePhase 4
    Registry statusCompleted

  • IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

    NCT01050478 · start 2010-03

    Registered record
    Registry ID
    NCT01050478
    Conditions
    Psychomotor Agitation; Acute Disease
    Interventions
    Paliperidone ER; Benzodiazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-12
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychomotor Agitation; Acute Disease
    InterventionPaliperidone ER; Benzodiazepine
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Paliperidone ER in First Episode Psychosis

    NCT01157585 · start 2010-02

    Registered record
    Registry ID
    NCT01157585
    Conditions
    First Episode Psychosis
    Interventions
    paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-02
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFirst Episode Psychosis
    Interventionpaliperidone ER
    PhasePhase 4
    Registry statusCompleted

  • A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

    NCT01060228 · start 2009-01

    Registered record
    Registry ID
    NCT01060228
    Conditions
    Schizophrenia; Epilepsy
    Interventions
    paliperidone ER; divalproex sodium ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Epilepsy
    Interventionpaliperidone ER; divalproex sodium ER
    PhasePhase 1
    Registry statusCompleted

  • Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)

    NCT00766064 · start 2008-09

    Registered record
    Registry ID
    NCT00766064
    Conditions
    Posttraumatic Stress Disorder
    Interventions
    Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-09
    Completion
    2009-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder
    InterventionPaliperidone
    PhasePhase 4
    Registry statusWithdrawn

  • Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

    NCT01577186 · start 2008-07

    Registered record
    Registry ID
    NCT01577186
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07
    Completion
    2009-06
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhasePhase 4
    Registry statusCompleted